Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | VHL T133fs |
Gene Variant Detail | |
Relevant Treatment Approaches | mTORC1 Inhibitor VEGFR Inhibitor (Pan) VEGFR2 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
VHL T133fs | clear cell renal cell carcinoma | predicted - sensitive | Belzutifan | Case Reports/Case Series | Actionable | In a clinical case study, Welireg (belzutifan) treatment resulted in a durable response lasting at least 1.5 years in a heavily-pretreated clear cell renal cell carcinoma patient harboring VHL T133fs (PMID: 38344974). | 38344974 |